

Lorinda Chung

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7215722/lorinda-chung-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

111
papers

5,899
citations

37
h-index

76
g-index

124
ext. papers

7,359
ext. citations

4.9
avg, IF

5.42
L-index

#	Paper	IF	Citations
111	Change in calcinosis over 1 year using the scleroderma clinical trials consortium radiologic scoring system for calcinosis of the hands in patients with systemic sclerosis.. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 53, 151980	5.3	1
110	Cytokine signatures differentiate systemic sclerosis patients at high versus low risk for pulmonary arterial hypertension.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 39	5.7	1
109	Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?. <i>Journal of Scleroderma and Related Disorders</i> , 2022 , 7, 7-23	2.3	0
108	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program.. <i>Pilot and Feasibility Studies</i> , 2022 , 8, 45	1.9	0
107	Ultrasound Detection of Calcinosis and Association With Ulnar Artery Occlusion in Patients With Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2021 , 73, 1332-1337	4.7	4
106	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021 , 22, 856	2.8	1
105	A Pilot Study to Evaluate the Safety and Efficacy of Treprostinil in the Treatment of Calcinosis in Systemic Sclerosis. <i>Rheumatology</i> , 2021 ,	3.9	1
104	Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries. <i>Arthritis and Rheumatology</i> , 2021 , 73, 837-847	9.5	9
103	A narrative review of imaging in calcinosis associated with systemic sclerosis. <i>Clinical Rheumatology</i> , 2021 , 40, 3867-3874	3.9	0
102	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 209-221	10.2	30
101	A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS2676-TPS2676	2.2	0
100	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 66-76	2.3	2
99	Rituximab Versus Mycophenolate in the Treatment of Recalcitrant Connective Tissue Disease-Associated Interstitial Lung Disease. <i>ACR Open Rheumatology</i> , 2021 , 3, 3-7	3.5	3
98	Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSICIS trial. <i>Respiratory Investigation</i> , 2021 , 59, 252-259	3.4	5
97	Does hand involvement in systemic sclerosis limit completion of patient-reported outcome measures?. <i>Clinical Rheumatology</i> , 2021 , 40, 965-971	3.9	1
96	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2021 , 60, 2615-2628	3.9	12
95	Promise and challenge of systemic sclerosis therapies. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 581-582 8.1		

94	Ultrasound evaluation of the hands and wrists in patients with systemic sclerosis: Osteophytosis is a major contributor to tender joints. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 735-740	5.3	2
93	A Novel Utility to Correct for Plate/Batch/Lot and Nonspecific Binding Artifacts in Luminex Data. <i>Journal of Immunology</i> , 2020 , 204, 3425-3433	5.3	3
92	Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 891-896	5.3	6
91	Drugs in phase I and phase II clinical trials for systemic sclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 349-362	5.9	7
90	Gastric antral vascular ectasia in systemic sclerosis: Association with anti-RNA polymerase III and negative anti-nuclear antibodies. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 938-942	5.3	3
89	Increased Mortality in Asians With Systemic Sclerosis in Northern California. <i>ACR Open Rheumatology</i> , 2020 , 2, 197-206	3.5	6
88	Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1350-1360	9.5	30
87	CD47 prevents the elimination of diseased fibroblasts in scleroderma. <i>JCI Insight</i> , 2020 , 5,	9.9	13
86	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. <i>JMIR Research Protocols</i> , 2020 , 9, e16799	2	3
85	Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry. <i>Clinical Rheumatology</i> , 2020 , 39, 93-102	3.9	3
84	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.. <i>Lancet Rheumatology, The</i> , 2020 , 2, e743-e753	14.2	13
83	Chromatin accessibility landscapes of skin cells in systemic sclerosis nominate dendritic cells in disease pathogenesis. <i>Nature Communications</i> , 2020 , 11, 5843	17.4	9
82	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020 , 72, 125-136	9.5	92
81	Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis. <i>Autoimmunity Reviews</i> , 2020 , 19, 102533	13.6	15
80	and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 552-562	11.5	23
79	Upper Extremity Angiographic Patterns in Systemic Sclerosis: Implications for Surgical Treatment. <i>Journal of Hand Surgery</i> , 2019 , 44, 990.e1-990.e7	2.6	3
78	An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 17-27	2.3	10
77	Management of Calcinosis Associated with Dermatomyositis. <i>Current Treatment Options in Rheumatology</i> , 2019 , 5, 242-257	1.3	1

76	Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. <i>Journal of Rheumatology</i> , 2019 , 46, 176-183	4.1	14
75	An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature. <i>Current Rheumatology Reports</i> , 2018 , 20, 10	4.9	15
74	Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis. <i>Clinics in Dermatology</i> , 2018 , 36, 508-524	3	14
73	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 563-570	2.4	31
72	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018 , 57, 370-381	3.9	36
71	Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1654-1660	9.5	8
70	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018 , 57, 1623-1631	3.9	26
69	Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis. <i>JAMA Dermatology</i> , 2018 , 154, 44-51	5.1	22
68	Pregnancy outcomes in adult patients with dermatomyositis and polymyositis. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 865-869	5.3	19
67	Calcinosis in scleroderma. <i>Current Opinion in Rheumatology</i> , 2018 , 30, 554-561	5.3	30
66	Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). <i>Chest</i> , 2018 , 154, 862-871	5.3	47
65	Non-invasive right ventricular load adaptability indices in patients with scleroderma-associated pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2018 , 8, 2045894018788268	2.7	18
64	Cutaneous and Systemic Findings Associated With Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis Patients. <i>Arthritis Care and Research</i> , 2017 , 69, 1909-1914	4.7	70
63	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1207-1218	2.4	71
62	Differential expression of hepatocyte growth factor in patients with systemic sclerosis-associated pulmonary arterial hypertension. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 225-230	2.3	
61	Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. <i>Medicine (United States)</i> , 2017 , 96, e8980	1.8	47
60	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. <i>Rheumatology</i> , 2017 , 56, 1884-1893	3.9	23
59	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 42-49	2.3	18

58	Calcinosis 2017 , 461-471		1
57	Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 106, 106-113	2.2	7
56	Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 46, 344-349	5.3	48
55	Intestinal pseudo-obstruction in patients with systemic sclerosis: an analysis of the Nationwide Inpatient Sample. <i>Rheumatology</i> , 2016 , 55, 654-8	3.9	17
54	Management of Calcinosis Associated with Systemic Sclerosis. <i>Current Treatment Options in Rheumatology</i> , 2016 , 2, 85-96	1.3	11
53	Corticosteroids in Myositis and Scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2016 , 42, 103-18, ix	2.4	9
52	Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity. <i>JCI Insight</i> , 2016 , 1, e89073	9.9	41
51	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. <i>Journal of Rheumatology</i> , 2016 , 43, 1672-9	4.1	163
50	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (FaSScinate): a phase 2, randomised, controlled trial. <i>Lancet, The</i> , 2016 , 387, 2630-2640	40	359
49	Characterization of patients with clinical overlap of morphea and systemic sclerosis: A case series. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 1272-4	4.5	5
48	Connective tissue disease-associated pulmonary arterial hypertension. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 295-313	2.4	13
47	Validation of the ICD-9-CM code for systemic sclerosis using updated ACR/EULAR classification criteria. <i>Scandinavian Journal of Rheumatology</i> , 2015 , 44, 253-5	1.9	17
46	Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 45, 309-14	5.3	16
45	Leukotriene B4 Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension. <i>Hypertension</i> , 2015 , 66, 1227-1239	8.5	49
44	Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 159	5.7	70
43	Surgical treatment of systemic sclerosis--is it justified to offer peripheral sympathectomy earlier in the disease process?. <i>Microsurgery</i> , 2015 , 35, 441-6	2.1	29
42	Calcinosis: pathophysiology and management. <i>Current Opinion in Rheumatology</i> , 2015 , 27, 542-8	5.3	60
41	Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 489-506	2.4	8

40	Validation of a novel radiographic scoring system for calcinosis affecting the hands of patients with systemic sclerosis. <i>Arthritis Care and Research</i> , 2015 , 67, 425-30	4.7	35
39	Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1 antibodies in adults with dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 449-55	4.5	108
38	Management of Digital Ischemia 2015 , 339-360		
37	Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. <i>Clinical Rheumatology</i> , 2014 , 33, 207-14	3.9	43
36	Cardiac arrhythmias and conduction defects in systemic sclerosis. <i>Rheumatology</i> , 2014 , 53, 1172-7	3.9	58
35	Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 400-1	4.5	21
34	International consensus criteria for the diagnosis of Raynaud's phenomenon. <i>Journal of Autoimmunity</i> , 2014 , 48-49, 60-5	15.5	118
33	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 706-14	5.7	40
32	Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. <i>Chest</i> , 2014 , 146, 1494-1504	5.3	94
31	Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <i>Chest</i> , 2014 , 146, 449-475	5.3	200
30	Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. <i>Arthritis Care and Research</i> , 2014 , 66, 489-95	4.7	100
29	Atherosclerotic cardiovascular disease in hospitalized patients with systemic sclerosis: higher mortality than patients with lupus and rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 323-7	4.7	26
28	Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. <i>JAMA Dermatology</i> , 2014 , 150, 724-9	5.1	70
27	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 44, 55-62	5.3	56
26	Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: utility of the University of California, San Diego, Shortness of Breath Questionnaire. <i>Arthritis Care and Research</i> , 2013 , 65, 454-63	4.7	14
25	2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2737-47		1636
24	Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. <i>Arthritis and Rheumatism</i> , 2013 , 65, 3194-201		131
23	Management of the hand in systemic sclerosis. <i>Journal of Hand Surgery</i> , 2013 , 38, 1012-6; quiz 1017	2.6	13

22	Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. <i>Arthritis Research and Therapy</i> , 2013 , 15, R7	5.7	35
21	Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis. <i>Current Rheumatology Reports</i> , 2013 , 15, 302	4.9	16
20	Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. <i>Chest</i> , 2013 , 144, 160-168	5.3	70
19	Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1335-42	2.4	67
18	Tyrosine kinases in inflammatory dermatologic disease. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 389-403	4.5	6
17	Survival in Pulmonary Hypertension Registries: Response. <i>Chest</i> , 2011 , 139, 1548-1549	5.3	2
16	Pathogenesis of dermatomyositis: role of cytokines and interferon. <i>Current Rheumatology Reports</i> , 2011 , 13, 225-32	4.9	37
15	Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis. <i>International Journal of Rheumatology</i> , 2011 , 2011, 201787	2	14
14	Vascular disease in systemic sclerosis. <i>International Journal of Rheumatology</i> , 2010 , 2010, 714172	2	4
13	Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. <i>Chest</i> , 2010 , 138, 1383-94	5.3	289
12	Molecular framework for response to imatinib mesylate in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 584-91		93
11	MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2009 , 60, 870-7		89
10	Pregnancy outcomes in systemic sclerosis, primary pulmonary hypertension, and sickle cell disease. <i>Obstetrics and Gynecology</i> , 2008 , 111, 927-34	4.9	136
9	Therapeutic options for digital ulcers in patients with systemic sclerosis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007 , 5, 460-5	1.2	16
8	Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. <i>Rheumatology</i> , 2007 , 46, 1808-13	3.9	54
7	A pilot trial of rituximab in the treatment of patients with dermatomyositis. <i>Archives of Dermatology</i> , 2007 , 143, 763-7		133
6	Digital ulcers in patients with systemic sclerosis. <i>Autoimmunity Reviews</i> , 2006 , 5, 125-8	13.6	89
5	Systemic and localized scleroderma. <i>Clinics in Dermatology</i> , 2006 , 24, 374-92	3	98

4	A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, 880-2	4-5	42
3	Successful use of rituximab for cutaneous vasculitis. <i>Archives of Dermatology</i> , 2006 , 142, 1407-10		32
2	Antibodies in scleroderma: direct pathogenicity and phenotypic associations. <i>Current Rheumatology Reports</i> , 2004 , 6, 156-63	4-9	44
1	Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. <i>Journal of Scleroderma and Related Disorders</i> , 239719832110644 ^{2,3}		1